Homology Medicines Inc FIXX

NAS: FIXX | ISIN: US4380831077   25/03/2024
0,935 USD (+0,77%)
(+0,77%)   25/03/2024

6 mei 2022 · FIXX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Homology Medicines, Inc. Investors with Substantial Losses Have Opportunity to Lead Case · Persbericht

28 april 2022 · FIXX LAWSUIT ALERT: Levi & Korsinsky Notifies Homology Medicines, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline · Persbericht

21 april 2022 · FIXX LAWSUIT ALERT: Levi & Korsinsky Notifies Homology Medicines, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline · Persbericht

14 april 2022 · FIXX LAWSUIT ALERT: Levi & Korsinsky Notifies Homology Medicines, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline · Persbericht

7 april 2022 · FIXX LAWSUIT ALERT: Levi & Korsinsky Notifies Homology Medicines, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline · Persbericht

3 april 2022 · FIXX DEADLINE: Investors with Substantial Losses Have Opportunity to Lead Homology Medicines, Inc. Class Action Lawsuit · Persbericht

31 maart 2022 · FIXX LAWSUIT ALERT: Levi & Korsinsky Notifies Homology Medicines, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline · Persbericht

31 maart 2022 · ALERT: Homology Medicines, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FIXX · Persbericht

29 maart 2022 · Bronstein, Gewirtz & Grossman, LLC Notifies Homology Medicines, Inc. (FIXX) Shareholders of Class Action and Encourages Investors to Contact the Firm · Persbericht

26 maart 2022 · Pomerantz Law Firm Announces the Filing of a Class Action Against Homology Medicines, Inc., and Certain Officers - FIXX · Persbericht

11 maart 2021 · Homology Medicines Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights · Persbericht

1 maart 2021 · Homology Medicines Regains Worldwide Rights to Ophthalmology Program Based on its In Vivo Nuclease-Free Gene Editing Platform · Persbericht

8 februari 2021 · Homology Medicines Announces First Presentation of Data with HMI-203 In Vivo Gene Therapy Development Candidate for Hunter Syndrome · Persbericht

Mijn selecties